AU2006228949A1 - Compositions for oral transmucosal delivery of metformin - Google Patents

Compositions for oral transmucosal delivery of metformin Download PDF

Info

Publication number
AU2006228949A1
AU2006228949A1 AU2006228949A AU2006228949A AU2006228949A1 AU 2006228949 A1 AU2006228949 A1 AU 2006228949A1 AU 2006228949 A AU2006228949 A AU 2006228949A AU 2006228949 A AU2006228949 A AU 2006228949A AU 2006228949 A1 AU2006228949 A1 AU 2006228949A1
Authority
AU
Australia
Prior art keywords
composition
subject
metformin
concentration
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006228949A
Other languages
English (en)
Inventor
Anna E. Gluskin
Muhammad Waseem Tahir Qazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
GENEREX PHARM Inc
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENEREX PHARM Inc, Generex Pharmaceuticals Inc filed Critical GENEREX PHARM Inc
Publication of AU2006228949A1 publication Critical patent/AU2006228949A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006228949A 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin Abandoned AU2006228949A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66647505P 2005-03-30 2005-03-30
US60/666,475 2005-03-30
PCT/CA2006/000472 WO2006102752A1 (en) 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin

Publications (1)

Publication Number Publication Date
AU2006228949A1 true AU2006228949A1 (en) 2006-10-05

Family

ID=37052910

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006228949A Abandoned AU2006228949A1 (en) 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin

Country Status (16)

Country Link
US (1) US20090069437A1 (https=)
EP (1) EP1863465A4 (https=)
JP (1) JP2008534523A (https=)
AR (1) AR052960A1 (https=)
AU (1) AU2006228949A1 (https=)
BR (1) BRPI0611555A2 (https=)
CA (1) CA2603450A1 (https=)
CR (1) CR9363A (https=)
IL (1) IL185931A0 (https=)
MX (1) MX2007012047A (https=)
NZ (1) NZ560990A (https=)
PE (1) PE20061245A1 (https=)
RU (2) RU2409357C2 (https=)
UY (1) UY29445A1 (https=)
WO (1) WO2006102752A1 (https=)
ZA (1) ZA200708834B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080025A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
CA2710815A1 (en) * 2008-01-16 2009-07-23 Janssen Pharmaceutica Nv Combination of metformin and an mtp inhibitor
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
WO2010149170A1 (en) * 2009-06-24 2010-12-29 Københavns Universitet Treatment of insulin resistance and obesity by stimulating glp-1 release
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP3696281A1 (en) * 2019-02-13 2020-08-19 Johann Wolfgang Goethe-Universität Frankfurt am Main Arginase as biomarker and drug target for pcos
WO2020227344A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of California Chloride intracellular channel 1 for regulation of food intake

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161428C (da) * 1985-05-10 1991-12-16 Fertin Lab As Fast, oralt cariesmodvirkende middel
DK365389D0 (da) * 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6517870B1 (en) * 1998-04-29 2003-02-11 Sumitomo Pharmaceuticals Company, Limited Oral formulation comprising biguanide and an organic acid
ES2206868T3 (es) * 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6344222B1 (en) * 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
BR0115390A (pt) * 2000-11-03 2004-02-25 Andrx Corp Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
AU2003272504A1 (en) * 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
KR20060108692A (ko) * 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형

Also Published As

Publication number Publication date
PE20061245A1 (es) 2007-01-06
WO2006102752A1 (en) 2006-10-05
RU2409357C2 (ru) 2011-01-20
UY29445A1 (es) 2006-10-02
AR052960A1 (es) 2007-04-11
MX2007012047A (es) 2007-12-12
CR9363A (es) 2008-02-12
IL185931A0 (en) 2008-02-09
RU2010139163A (ru) 2012-03-27
BRPI0611555A2 (pt) 2010-09-21
US20090069437A1 (en) 2009-03-12
EP1863465A4 (en) 2010-12-15
EP1863465A1 (en) 2007-12-12
NZ560990A (en) 2009-02-28
JP2008534523A (ja) 2008-08-28
ZA200708834B (en) 2008-11-26
RU2007139886A (ru) 2009-05-10
CA2603450A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
JP5179757B2 (ja) 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
AU2018217251A1 (en) Buccal and/or sublingual therapeutic formulation
WO2009080023A1 (en) Compressed chewing gum comprising peptide
SG174785A1 (en) Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20090069437A1 (en) Compositions for Oral Transmucosal Delivery of Metformin
CN115887379A (zh) 一种维生素d3喷雾剂及其制备方法
US20110274728A1 (en) Compositions and Methods for Alleviating Hyposalivation and for Providing Oral Comfort
JPH05501854A (ja) 親油性薬剤の非侵襲性用量対効果式投与のための方法及び組成物
Ughade et al. Medicated chewing gum: Modern approach to mucosal drug delivery
US20030108605A1 (en) Mineral supplement
US20190099368A1 (en) Chewable dosage forms containing sitagliptin and metformin
J Tangso et al. Confectionery-based dose forms
US20160361257A1 (en) Composition for increasing testosterone levels and enhancing libido
RU2389493C2 (ru) Композиция и способ для повышения уровня глюкозы в крови
Makwana et al. Chewing gum: A modern approach to oral mucosal drug delivery
US11096890B2 (en) Chewable dosage forms containing sitagliptin and metformin
MXPA06009296A (es) Composiciones para suministro de agentes hipnoticos a traves de la mucosa oral y sus metodos de uso.
Lakkis Encapsulation and controlled release applications in confectionery and oral care products
US20080085331A1 (en) Composition and method for raising blood glucose level
Singh et al. A REVIEW ON DIFFERENT FORMULATIONS OF BACLOFEN FOR SPASTICITY
EP1054674B1 (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
CA2562821A1 (en) Composition and method for raising blood glucose level
US20150030685A1 (en) Sugar-Free Oral Transmucosal Fentanyl Citrate Lozenge Dosage Forms

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application